This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.08% per year. These returns cover a period from January 1, 1988 through May 6, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Dexcom's (DXCM) Digital Network Benefits From Latest FDA Nod
by Zacks Equity Research
Recent regulatory clearance of Dexcom's (DXCM) real-time APIs is expected to aid diabetics as well as their care providers in accessing GCM data.
New Strong Sell Stocks for July 13th
by Zacks Equity Research
ONEM, BABA, DXCM, ORAN, and MTH have been added to the Zacks Rank #5 (Strong Sell) List on July 13, 2021
New Strong Sell Stocks for July 6th
by Zacks Equity Research
DXCM, GP, PHR, RAD, and MAXR have been added to the Zacks Rank #5 (Strong Sell) List on July 6, 2021
Diabetes Space Thrives on CGM Devices in 2021: 3 Stocks in Focus
by Debanjana Dey
CGM device stocks Medtronic (MDT), Dexcom (DXCM) and Tandem Diabetes (TNDM) are expected to continue their run over the next few months.
Dexcom's (DXCM) G6 CGM System Gets Coverage in British Columbia
by Zacks Equity Research
Dexcom's (DXCM) CGM is expected to simplify diabetes management due to increasing access to the life-changing technology.
DexCom (DXCM) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
DexCom's (DXCM) first-quarter results benefit from domestic and international revenue growth.
DexCom (DXCM) Surpasses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
DexCom (DXCM) delivered earnings and revenue surprises of 6.45% and 4.63%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Medical Products' Apr 29 Earnings Roster: TMO, BAX & More
by Trina Mukherjee
The Medical Product companies' first-quarter results are likely to reflect robust earnings and revenue growth on solid base business recovery.
Zacks.com featured highlights include: MercadoLibre, HealthEquity, DexCom, StoneCo and Las Vegas Sands
by Zacks Equity Research
Zacks.com featured highlights include: MercadoLibre, HealthEquity, DexCom, StoneCo and Las Vegas Sands
DexCom (DXCM) is in Overbought Territory: What's Next?
by Zacks Equity Research
DexCom (DXCM) has moved higher as of late, but there could definitely be trouble on the horizon for this company
5 Toxic Stocks That Could Break the Bank
by Rimmi Singhi
Steer clear of toxic stocks like MELI, HQY, DXCM, STNE and LVS to safeguard your portfolio.
DexCom (DXCM) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
DexCom's (DXCM) first-quarter results are likely to reflect rising global awareness of its real-time CGM.
Analysts Estimate DexCom (DXCM) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
DexCom (DXCM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Keep Your Portfolio Protected From These Toxic Stocks
by Rimmi Singhi
Toxic stocks are vulnerable to external shocks and are burdened with huge debts. It's important to ensure that you safeguard your portfolio from such stocks.
4 Toxic Stocks That Could Ruin Your Portfolio
by Rimmi Singhi
Toxic stocks usually carry huge debt load and are vulnerable to external shocks. They should be timely discarded from one's portfolio to avoid wealth erosion.
DexCom (DXCM) Q4 Earnings Match Estimates, Revenues Beat
by Zacks Equity Research
DexCom's (DXCM) fourth-quarter results benefit from domestic and international revenue growth.
DexCom (DXCM) Meets Q4 Earnings Estimates
by Zacks Equity Research
DexCom (DXCM) delivered earnings and revenue surprises of 0.00% and 1.88%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Medical Products' Feb 11 Earnings Roster: DXCM, LH & More
by Trina Mukherjee
The Medical Product companies' fourth-quarter results are likely to reflect huge adoption of COVID-19 related healthcare-support products and services despite the impact of the ongoing pandemic.
DexCom (DXCM) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
DexCom's (DXCM) fourth-quarter results are likely to reflect rising global awareness of its real-time CGM.
Stock Market News for Jan 15, 2021
by Zacks Equity Research
Benchmarks closed in the red on Thursday, as rise in weekly initial jobless claims suggested that economic growth is stalling again.
DexCom (DXCM) Posts Solid Preliminary Q4 and 2020 Revenues
by Zacks Equity Research
DexCom (DXCM) posts solid fourth-quarter and full-year 2020 revenue data on the back of resilience shown in the face of the COVID-19 induced challenges.
DexCom (DXCM) Gains But Lags Market: What You Should Know
by Zacks Equity Research
DexCom (DXCM) closed the most recent trading day at $388.09, moving +0.24% from the previous trading session.
DexCom (DXCM) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, DexCom (DXCM) closed at $355.02, marking a -0.27% move from the previous day.
DexCom (DXCM) Gains As Market Dips: What You Should Know
by Zacks Equity Research
DexCom (DXCM) closed at $358.57 in the latest trading session, marking a +0.18% move from the prior day.
Zacks Industry Outlook Highlights: Teladoc, PRA Health and DexCom
by Zacks Equity Research
Zacks Industry Outlook Highlights: Teladoc, PRA Health and DexCom